Investigating the effects of age, IQ, dosing, and anthropometric measures on the treatment persistence in long-term methylphenidate use

References

• Ayano G, Yohannes K, Abraha M. Epidemiology of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Africa: a systematic review and Meta-analysis. Ann Gen Psychiatry. 2020;19:21.
   PubMed Web of Science ®Google Scholar
• Brahmbhatt K, Hilty DM, Hah M, et al. Diagnosis and treatment of attention deficit hyperactivity disorder during adolescence in the primary care setting: a concise review. J Adolesc Health. 2016;59(2):135–143.
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Hagan JF, Jr., Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of Attention-Deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.
   PubMed Web of Science ®Google Scholar
• Hamed AM, Kauer AJ, Stevens HE. Why the diagnosis of attention deficit hyperactivity disorder matters. Front Psychiatry. 2015;6:168.
   PubMed Web of Science ®Google Scholar
• Stevens JR, Wilens TE, Stern TA. Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord. 2013;15(2):PCC.12f01472.
   PubMedGoogle Scholar
• Taylor E, Chadwick O, Heptinstall E, et al. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996;35(9):1213–1226.
   PubMed Web of Science ®Google Scholar
• Huntley Z, Maltezos S, Williams C, et al. Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units. BMC Psychiatry. 2012;12:223.
   PubMed Web of Science ®Google Scholar
• Ercan ES, Unsel-Bolat G, Tufan AE, et al. Effect of impairment on the prevalence and comorbidities of attention deficit hyperactivity disorder in a national survey: nation-wide prevalence and comorbidities of ADHD. J Atten Disord. 2022;26(5):674–684.
   PubMed Web of Science ®Google Scholar
• Kraut AA, Langner I, Lindemann C, et al. Comorbidities in ADHD children treated with methylphenidate: a database study. BMC Psychiatry. 2013;13:11.
   PubMed Web of Science ®Google Scholar
• Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999;38(4):402–409.
   PubMed Web of Science ®Google Scholar
• Storebo OJ, Krogh HB, Ramstad E, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with Meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.
   PubMed Web of Science ®Google Scholar
• Kang KD, Yun SW, Chung U, et al. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder. Hum Psychopharmacol Clin Exp. 2016;31(2):76–82.
   PubMed Web of Science ®Google Scholar
• Pliszka S, AACAP Work Group on Quality Issues Issues AWGoQ. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
   PubMed Web of Science ®Google Scholar
• Izmir SBI, Ipci M, Ercan ES. Methylphenidate significantly improves neurocognitive impairments in children with ADHD. Psychiatry Res. 2022;311:114492.
   PubMed Web of Science ®Google Scholar
• Cheung K, Dierckx B, El Marroun H, et al. Methylphenidate treatment adherence and persistence in children in The Netherlands. J Child Adolesc Psychopharmacol. 2021;31(3):205–213.
   PubMed Web of Science ®Google Scholar
• Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, et al. Weight, height, and body mass index in patients with Attention-Deficit/hyperactivity disorder treated with methylphenidate. J Child Adolesc Psychopharmacol. 2017;27(8):723–730.
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Bailey-Davis L, Bandeen-Roche K, et al. Attention deficit disorder, stimulant use, and childhood body mass index trajectory. Pediatrics. Apr. 2014;133(4):668–676.
   PubMed Web of Science ®Google Scholar
• Carucci S, Balia C, Gagliano A, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and Meta-analysis. Neurosci Biobehav Rev. Jan. 2021;120:509–525.
   PubMed Web of Science ®Google Scholar
• McCarthy S, Neubert A, Man KKC, et al. Effects of long-term methylphenidate use on growth and blood pressure: results of the german health interview and examination survey for children and adolescents (KiGGS). BMC Psychiatry. 2018;18(1):327.
   PubMedGoogle Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543–1569.
   PubMed Web of Science ®Google Scholar
• Semerci B, Taskiran S, Tufan E, et al. Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: a preliminary study. Atten Defic Hyperact Disord. 2016;8(3):139–147.
   PubMedGoogle Scholar
• Gau SS, Shen HY, Chou MC, et al. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006;16(3):286–297.
   PubMed Web of Science ®Google Scholar
• Nagae M, Nakane H, Honda S, et al. Factors affecting medication adherence in children receiving outpatient pharmacotherapy and parental adherence. J Child Adolesc Psychiatr Nurs. 2015;28(2):109–117.
   PubMedGoogle Scholar
• Ercan ES, Varan A, Deniz U. Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: a preliminary report. J Child Adolesc Psychopharmacol. 2005;15(2):203–219.
   PubMed Web of Science ®Google Scholar
• Coletti DJ, Pappadopulos E, Katsiotas NJ, et al. Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(3):226–237.
   PubMed Web of Science ®Google Scholar
• Ayaz M, Ayaz AB, Soylu N, et al. Medication persistence in Turkish children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(8):442–447.
   PubMed Web of Science ®Google Scholar
• Hugtenburg JG, Witte I, Heerdink ER. Determinants of compliance with methylphenidate therapy in children. Acta Paediatr. 2006;95(12):1674–1676.
   PubMed Web of Science ®Google Scholar
• Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin. 2011;27(2):13–22.
   PubMedGoogle Scholar
• Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184–191.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Yang KC, Lee SY, et al. Initiation and persistence of pharmacotherapy for youths with attention deficit hyperactivity disorder in Taiwan. PLoS One. 2016;11(8):e0161061.
   PubMed Web of Science ®Google Scholar
• Miller AR, Lalonde CE, McGrail KM. Children’s persistence with methylphenidate therapy: a population-based study. Can J Psychiatry. 2004;49(11):761–768.
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Donyai P. Drug holidays from ADHD medication: international experience over the past four decades. J Atten Disord. 2015;19(7):551–568.
   PubMed Web of Science ®Google Scholar
• Wechsler D. Manual for the Wechsler intelligence scale for children – revised. San Antonio (TX): Psychological Corporation; 1974.
   Google Scholar
• Turgay A. Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers. London: Integrative Therapy Institute Publication; 1994.
   Google Scholar
• Ercan E, Amado S, Somer O, et al. Development of a test battery for the assessment of attention deficit hyperactivity disorder. Turk J Child Adolescent Mental Health. 2001;8:132–144.
   Google Scholar
• Neyzi O, Bundak R, Gökçay G, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol. 2015;7(4):280–293.
   PubMed Web of Science ®Google Scholar
• Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1(4):274–278.
   PubMedGoogle Scholar
• Zetterqvist J, Asherson P, Halldner L, et al. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128(1):70–77.
   PubMed Web of Science ®Google Scholar
• Chen CY, Yeh HH, Chen KH, et al. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(3):265–273.
   PubMed Web of Science ®Google Scholar
• Wong IC, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13(50):iii–120.
   PubMed Web of Science ®Google Scholar
• Both C, Mechler K, Niemeyer L, et al. Medication adherence in adolescents with psychiatric disorders. Z Kinder Jugendpsychiatr Psychother. 2021;49(4):295–306.
   PubMed Web of Science ®Google Scholar
• Skoglund C, Brandt L, Almqvist C, et al. Factors associated with adherence to methylphenidate treatment in adult patients with Attention-Deficit/hyperactivity disorder and substance use disorders. J Clin Psychopharmacol. 2016;36(3):222–228.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24–29.
   PubMed Web of Science ®Google Scholar
• Huss M, Duhan P, Gandhi P, et al. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat. 2017;13:1741–1751.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord. 2007;11(2):157–166.
   PubMedGoogle Scholar
• Frank E, Ozon C, Nair V, et al. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459-68–e1468.
   PubMed Web of Science ®Google Scholar
• Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15(7):371.
   PubMed Web of Science ®Google Scholar
• Ferrin M, Ruiz-Veguilla M, Blanc-Betes M, et al. Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2012;21(7):387–401.
   PubMed Web of Science ®Google Scholar
• Subcommittee on Attention-Deficit/Hyperactivity D, Steering Committee on Quality I, Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022.
   PubMed Web of Science ®Google Scholar
• van den Ban E, Souverein PC, Swaab H, et al. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in The Netherlands. ADHD Atten Def Hyp Disord. 2010;2(4):213–220.
   PubMedGoogle Scholar
• Toomey SL, Sox CM, Rusinak D, et al. Why do children with ADHD discontinue their medication? Clin Pediatr (Phila). 2012;51(8):763–769.
   PubMed Web of Science ®Google Scholar